Understanding the Interplay Between Medicaid and 340B

owner image
Owner:
PharmaVoice
Wednesday, December 11, 2019 | 3pm EST (US and Canada) / December 12, 4am CST (China) / 8pm GMT (UK) 60 min | English
Keywords: ,

Webinar Details

Gain an Understanding of the Complexities of the 340B Program—and Learn Key Findings from Manatt’s 50-State Survey on the Interplay Between the 340B and Medicaid Programs. 

The 340B drug discount program—which requires drug manufacturers to provide outpatient drugs to eligible healthcare entities at sharply reduced prices—continues to expand, with the number of participating covered entities almost doubling in the past five years to 38,000, according to the Government Accountability Office.  As the 340B program has grown, so has the controversy around it.  Supporters believe that it is vital to helping hospitals and other covered entities care for their uninsured and underinsured patients, while critics assert that it is being abused.

Both sides can agree, however, that the program can be very confusing to navigate.  The interplay between 340B and Medicaid can be particularly challenging, especially in states providing drug coverage through Medicaid managed care organizations (MCOs).  The use of contract pharmacies adds to the complexities of identifying 340B drugs.

In a new webinar, Manatt will focus on the complexities of the 340B program.  We also will review key findings from our comprehensive 50-state survey on the interplay between the 340B and Medicaid programs.

Key Takeaways:

The webinar will answer key questions, including:

  • What is the 340B program, and how does it work?
  • What is the interplay between 340B and Medicaid—and what are the resulting challenges?
  • How do contract pharmacy arrangements add to the complications?
  • How much are states reimbursing 340B covered entities and contract pharmacies for 340B drugs?
  • What methodologies are states employing to avoid duplicate discounts?

Audience:
This program is for to anyone who would benefit from a deeper understanding of the 340B drug discount program, including executives and team members from:

  • Corporate management
  • Brand and Product Management
  • Marketing/Sales Management
  • Legal
  • Regulatory Affairs
  • Health Policy
  • Compliance

More Information

Webinar Type: Recorded

Speakers

Related Webinars